scholarly journals Pentraxin 3, a novel inflammatory marker in heart failure patients: its expression in whole blood as a function of clinical severity

2019 ◽  
Vol 2 (1) ◽  
Author(s):  
Cabiati M ◽  
Salvadori C ◽  
Verde A ◽  
Del Ry S
Keyword(s):  
Heart Failure ◽  
Whole Blood ◽  
Inflammatory Marker ◽  
Clinical Severity ◽  
Pentraxin 3 ◽  
Heart Failure Patients

scholarly journals Galectin-3 in Predicting Mortality of Heart Failure: A Systematic Review and Meta-Analysis

2021 ◽  
Vol 24 (2) ◽  
pp. E327-E332
Author(s):  
Chenxia Wu ◽  
Zhengtian Lv ◽  
Xinyi Li ◽  
Xinbing Zhou ◽  
Wei Mao ◽  
...  
Keyword(s):  
Heart Failure ◽  
Systematic Review ◽  
Chronic Heart Failure ◽  
Cardiac Fibrosis ◽  
Inflammatory Marker ◽  
Meta Analysis ◽  
Cochrane Library ◽  
Heart Failure Patients ◽  
Galectin 3 ◽  
The Cochrane Library

Background: In recent years, galectin-3, an inflammatory marker, has been demonstrated to be closely related to cardiac fibrosis and heart failure. The purpose of this systematic review and meta-analysis is to define galectin-3 in predicting mortality of heart failure. Methods: PubMed, Embase, and the Cochrane Library were searched. A total of 1540 studies were identified, and of these studies, 19 involving 9217 patients were included in our meta-analysis. Results: The diagnostic hazard ratios of galectin-3 in predicting mortality in chronic heart failure patients was 1.13 (95% CI,:1.07-1.21 ) and 2.17 (95% CI:1.27-3.08) in acute heart failure (HF) patients. Conclusions: Our meta-analysis shows that elevated levels of galectin-3 are associated with higher mortality in both acute and chronic heart failure patients.

scholarly journals Transcriptomic Profiling of the Four Adenosine Receptors in Human Leukocytes of Heart Failure Patients

2013 ◽  
Vol 2013 ◽  
pp. 1-6 ◽  
Author(s):  
Manuela Cabiati ◽  
Raffaele Caruso ◽  
Alessandro Verde ◽  
Laura Sabatino ◽  
Maria-Aurora Morales ◽  
...  
Keyword(s):  
Heart Failure ◽  
Clinical Trials ◽  
Drug Therapy ◽  
Mrna Expression ◽  
Adenosine Receptors ◽  
Healthy Subjects ◽  
Clinical Severity ◽  
Transcriptomic Profiling ◽  
Human Leukocytes ◽  
Heart Failure Patients

In this study the transcriptomic profiling of adenosine receptors (ARs) in human leukocytes of heart failure (HF) patients as a function of clinical severity, assessing the possible changes with respect to healthy subjects (C), was evaluated. Total RNA was extracted from leukocytes ofC(n=8) and of HF patients (NYHA I-IIn=9; NYHA III-IVn=14) with a PAXgene Blood RNA Kit. An increase as a function of clinical severity was observed in each AR (A1R:C=0.02±0.009, NYHAI-II=0.21±0.09, NYHAIII-IV=3.6±1.3,P=0.03  Cversus NYHA III-IV,P=0.02NYHA I-II versus NYHA III-IV; A2aR:C=0.2±0.05, NYHAI-II=0.19±0.04, NYHAIII-IV=1.32±0.33,P=0.005  Cversus NYHA III-IV,P=0.003NYHA I-II versus NYHA III-IV; A2bR:C=1.78±0.36, NYHAI-II=1.35±0.29, NYHAIII-IV=4.07±1.21,P=0.03: NYHA I-II versus NYHA III-IV; A3R:C=0.76±0.21, NYHAI-II=0.94±0.19, NYHAIII-IV=3.14±0.77,P=0.01  Cversus NYHA III-IV and NYHA I-II versus NYHA III-IV, resp.). The mRNA expression of the ectonucleoside triphosphate diphosphohydrolase (CD39) and the ecto-5′-nucleotidase (CD73) were also evaluated. They resulted up-regulated. These findings show that components of adenosine metabolism and signalling are altered to promote adenosine production and signalling in HF patients. Thus, HF may benefit from adenosine-based drug therapy after confirmation by clinical trials.

scholarly journals Intestinal Microbiota in Patients with Chronic Heart Failure and Systolic Dysfunction

2020 ◽  
Vol 30 (2) ◽  
pp. 35-44
Author(s):  
M. V. Fadeeva ◽  
A. V. Kudryavtseva ◽  
G. S. Krasnov ◽  
M. R. Skhirtladze ◽  
V. T. Ivashkin
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Intestinal Microbiota ◽  
Contractile Function ◽  
Inflammatory Marker ◽  
Systolic Dysfunction ◽  
Control Group ◽  
Microbial Composition ◽  
Heart Failure Patients ◽  
Echocardiographic Examination

Aim. To study the composition of the intestinal microbiota in patients with chronic heart failure (CHF), as well as a relationship between the features of the CHF clinical course and changes in the microbial composition of the colon.Materials and methods. The study included 60 heart failure patients with systolic dysfunction diagnosed according to the results of echocardiographic examination. The control group consisted of 20 patients comparable to the main group by gender, age and underlying diseases in the absence of CHF. In all patients, the severity of CHF symptoms was assessed using a clinical assessment scale. The levels of the N-terminal fragment of the cerebral natriuretic peptide (NT-proBNP) and C-reactive protein (CRP) were determined. Echocardiographic examination and, if indicated, Holter ECG monitoring were performed. The intestinal microbiota in stool samples was studied by sequencing the 16S gene of ribosomal RNA (rRNA).Results. In comparison with the control group, CHF patients showed a decrease in the relative content of Tenericutes (p = 0.02, Mann—Whitney test) and an increase in the proportion of Euryarchaeota (p = 0.02) and Firmicutes (p = 0.03). At the family level, an increase in the proportion of Methanobacteriaceae (p = 0.03) and a decrease in the proportion of Pseudomonadaceae (p = 0.01) and Moraxellaceae (p = 0.01) were noted. No dependence of the intestinal microflora composition on the functional class of heart failure was observed. However, a correlation was revealed between the relative number of certain bacterial families and the severity of impaired contractile function, the level of the inflammatory marker and the biochemical marker of heart failure.Conclusions. The obtained data indicate differences in the intestinal microbiota composition in patients with and without heart failure. A correlation between the number of some bacterial families and various laboratory and instrumental indicators assessed in heart failure patients was revealed. Further research into the effect of intestinal microbiota on the course of heart failure appears to be promising for improving treatment methods.

scholarly journals Role of serum interleukin-6 in heart failure

2018 ◽  
Vol 5 (4) ◽  
pp. 936 ◽  
Author(s):  
Smita Amol Deokar ◽  
Sucheta P. Dandekar ◽  
Ganesh A. Shinde ◽  
Surekha S. Prabhu ◽  
Mugdha Patawardhan
Keyword(s):  
Heart Failure ◽  
Cardiovascular Disease ◽  
Cardiovascular Diseases ◽  
Interleukin 6 ◽  
Inflammatory Marker ◽  
Serum Analysis ◽  
Heart Failure Patients ◽  
Growing Body ◽  
Age And Sex

Background: A growing body of evidence suggests that inflammation plays the key role in different cardiovascular diseases. But very study has been done so far in relation to serum interleukin-6 in heart failure patients.  The aim of the study was to measure serum interleukin-6 in heart failure patients.Methods: Total 22 heart failure patients and 22 age and sex matched controls were included in this study from August 2015 to June 2016 for serum analysis of interleukin-6.Results: serum interleukin-6 was significantly [median(IQR) 14.3(26.2) pg/mL] increased in heart failure patients compared to age and sex matched controls [median(IQR) 0(2.4) pg/mL].Conclusions: Even though little is known about function of interleukin-6 in heart failure patients, this study shows that increased level of IL-6 in heart failure patients plays an important role as a pro-inflammatory marker in development of cardiovascular disease i.e. heart failure.

Sign in / Sign up

Export Citation Format

Share Document